Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
12 February 2008Website:
http://www.mimedx.comNext earnings report:
01 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
MDXG Latest News
MiMedx Group, Inc. (NASDAQ: MDXG) held its Q1 2024 Earnings Conference Call on April 30, 2024 at 4:30 PM ET. The call included presentations from Matt Notarianni, Joe Capper, and Doug Rice. Participants on the call included analysts from Craig Hallum, Lake Street Capital Markets, Mizuho, Northland Capital Markets, and H.C. Wainwright. The operator thanked everyone for joining the call.
MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript
MiMedx Group said on Friday it had received a warning letter from the U.S. Food and Drug Administration related to the classification of its placental-derived tissue product Axiofill, and its shares fell 7% after the bell.
MiMedx Group, Inc. (NASDAQ:MDXG ) Q3 2023 Earnings Call October 30, 2023 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joseph H. Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C.
MiMedx Group, Inc. (NASDAQ:MDXG ) Q1 2023 Earnings Conference Call May 2, 2023 5:00 PM ET Company Participants Matt Notarianni - Head, IR Joe Capper - CEO Pete Carlson - CFO Conference Call Participants Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Good afternoon and thank you for standing by.
What type of business is MiMedx?
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
What sector is MiMedx in?
MiMedx is in the Healthcare sector
What industry is MiMedx in?
MiMedx is in the Biotechnology industry
What country is MiMedx from?
MiMedx is headquartered in United States
When did MiMedx go public?
MiMedx initial public offering (IPO) was on 12 February 2008
What is MiMedx website?
https://www.mimedx.com
Is MiMedx in the S&P 500?
No, MiMedx is not included in the S&P 500 index
Is MiMedx in the NASDAQ 100?
No, MiMedx is not included in the NASDAQ 100 index
Is MiMedx in the Dow Jones?
No, MiMedx is not included in the Dow Jones index
When does MiMedx report earnings?
The next expected earnings date for MiMedx is 01 August 2024